IDEXX Laboratories Inc $ 284.33 -3.29 (-1.14%)
Volume:
94,712
Avg Vol (1m):
496,808
Market Cap $:
24.39 Bil
Enterprise Value $:
25.30 Bil
P/E (TTM):
58.99
P/B:
120.64
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.1 | ||
| Equity-to-Asset | 0.12 | ||
| Debt-to-Equity | 4.98 | ||
| Debt-to-EBITDA | 1.58 | ||
| Interest Coverage | 17.15 | ||
| Piotroski F-Score | 8 | ||
| Altman Z-Score | 13.2 | ||
| Beneish M-Score | -2.46 | ||
| WACC vs ROIC | |||
Profitability Rank | 10/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 23.5 | ||
| Net Margin % | 17.99 | ||
| ROE % | 510.57 | ||
| ROA % | 25.66 | ||
| ROC (Joel Greenblatt) % | 80.33 | ||
| 3-Year Revenue Growth Rate | 13.5 | ||
| 3-Year EBITDA Growth Rate | 18 | ||
| 3-Year EPS without NRI Growth Rate | 27.6 |
Valuation Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 58.99 | ||
| Forward PE Ratio | 53.48 | ||
| PE Ratio without NRI | 58.99 | ||
| Price-to-Owner-Earnings | 75.82 | ||
| PB Ratio | 120.64 | ||
| PS Ratio | 10.6 | ||
| Price-to-Free-Cash-Flow | 85.93 | ||
| Price-to-Operating-Cash-Flow | 56.73 | ||
| EV-to-EBIT | 45.74 | ||
| EV-to-EBITDA | 39.59 | ||
| EV-to-Revenue | 10.76 | ||
| PEG Ratio | 3.32 | ||
| Shiller PE Ratio | 113.52 | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.8 | ||
| Days Inventory | 67.84 | ||
| Days Sales Outstanding | 41.66 | ||
| Days Payable | 27.13 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Intrinsic-Value-Projected-FCF | 6.84 | ||
| Price-to-Intrinsic-Value-DCF (Earnings Based) | 2.96 | ||
| Price-to-Median-PS-Value | 2.43 | ||
| Price-to-Peter-Lynch-Fair-Value | 3.1 | ||
| Earnings Yield (Greenblatt) % | 2.19 | ||
| Forward Rate of Return (Yacktman) % | 19.97 |